The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

If this EUA application is authorised, children 6 months to under 5 years of age would receive a primary series consisting of two 3-µg doses of the original Pfizer/BioNTech COVID-19 Vaccine ...

Healthcare & Pharmaceuticalscategory US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug June 17, 2024 Reuters, the news and media division of Thomson Reuters, ...

Pfizer Inc. and BioNTech SE said Friday that a Phase 3 trial of their COVID-19-influenza combination vaccine candidate met one of its two objectives. The trial’s two primary objectives were for ...

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

GDANSK, Aug 19 (Reuters) - BioNTech (22UAy.DE), opens new tab on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its ...

Professors Ugur Sahin and Ozlem Tureci co-founded the German company BioNTech in 2008, exploring new technology involving messenger RNA (mRNA), to treat cancer. When the pandemic struck they ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...

Cambridge-based Moderna (Nasdaq: MRNA), as well as Pfizer and BioNTech, said their updated ... larger Cambridge HQ Related: Take a look inside Moderna's new, larger Cambridge HQ ...